Virtus ETF Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-100
| Closed | -$56.2K | – | 539 |
|
|
2025
Q3 | $56.2K | Buy |
+100
| New | +$56.5K | 0.03% | 370 |
|
|
2025
Q1 | – | Sell |
-472
| Closed | -$336K | – | 714 |
|
|
2024
Q4 | $336K | Buy |
472
+151
| +47% | +$127K | 0.14% | 220 |
|
|
2024
Q3 | $337K | Sell |
321
-954
| -75% | -$1.06M | 0.16% | 219 |
|
|
2024
Q2 | $1.34M | Buy |
1,275
+47
| +4% | +$45.6K | 0.66% | 2 |
|
|
2024
Q1 | $1.18M | Buy |
1,228
+123
| +11% | +$117K | 0.63% | 4 |
|
|
2023
Q4 | $971K | Sell |
1,105
-306
| -22% | -$252K | 0.62% | 2 |
|
|
2023
Q3 | $1.16M | Sell |
1,411
-3
| -0.2% | -$2.36K | 0.71% | 1 |
|
|
2023
Q2 | $1.02M | Sell |
1,414
-211
| -13% | -$163K | 0.6% | 6 |
|
|
2023
Q1 | $1.34M | Buy |
1,625
+144
| +10% | +$109K | 0.73% | 1 |
|
|
2022
Q4 | $1.07M | Sell |
1,481
-94
| -6% | -$69.4K | 0.56% | 5 |
|
|
2022
Q3 | $1.08M | Buy |
1,575
+91
| +6% | +$57.3K | 0.43% | 84 |
|
|
2022
Q2 | $877K | Buy |
1,484
+930
| +168% | +$605K | 0.33% | 91 |
|
|
2022
Q1 | $387K | Hold |
554
| – | – | 0.17% | 154 |
|
|
2021
Q4 | $350K | Sell |
554
-307
| -36% | -$189K | 0.13% | 182 |
|
|
2021
Q3 | $521K | Sell |
861
-83
| -9% | -$51.5K | 0.23% | 131 |
|
|
2021
Q2 | $527K | Sell |
944
-303
| -24% | -$154K | 0.22% | 132 |
|
|
2021
Q1 | $590K | Buy |
1,247
+31
| +3% | +$15.1K | 0.25% | 127 |
|
|
2020
Q4 | $587K | Buy |
1,216
+222
| +22% | +$120K | 0.24% | 122 |
|
|
2020
Q3 | $556K | Buy |
994
+13
| +1% | +$7.88K | 0.29% | 121 |
|
|
2020
Q2 | $612K | Sell |
981
-671
| -41% | -$381K | 0.29% | 113 |
|
|
2020
Q1 | $806K | Sell |
1,652
-151
| -8% | -$62.3K | 0.33% | 124 |
|
|
2019
Q4 | $677K | Sell |
1,803
-468
| -21% | -$157K | 0.11% | 157 |
|
|
2019
Q3 | $630K | Sell |
2,271
-381
| -14% | -$113K | 0.13% | 170 |
|
|
2019
Q2 | $830K | Buy |
2,652
+581
| +28% | +$193K | 0.18% | 178 |
|
|
2019
Q1 | $850K | Buy |
2,071
+480
| +30% | +$198K | 1.81% | 14 |
|
|
2018
Q4 | $594K | Sell |
1,591
-889
| -36% | -$325K | 0.1% | 46 |
|
|
2018
Q3 | $1M | Buy |
2,480
+167
| +7% | +$63.6K | 0.1% | 49 |
|
|
2018
Q2 | $798K | Sell |
2,313
-39
| -2% | -$12.2K | 0.71% | 28 |
|
|
2018
Q1 | $810K | Sell |
2,352
-174
| -7% | -$60.5K | 0.7% | 71 |
|
|
2017
Q4 | $950K | Buy |
2,526
+355
| +16% | +$144K | 1.19% | 34 |
|
|
2017
Q3 | $971K | Hold |
2,171
| – | – | 0.13% | 62 |
|
|
2017
Q2 | $1.07M | Sell |
2,171
-543
| -20% | -$238K | 0.16% | 58 |
|
|
2017
Q1 | $1.05M | Buy |
2,714
+261
| +11% | +$96.7K | 0.19% | 62 |
|
|
2016
Q4 | $900K | Buy |
2,453
+755
| +44% | +$287K | 0.27% | 70 |
|
|
2016
Q3 | $683K | Buy |
1,698
+213
| +14% | +$85.4K | 0.33% | 53 |
|
|
2016
Q2 | $519K | Buy |
1,485
+428
| +40% | +$165K | 0.39% | 53 |
|
|
2016
Q1 | $381K | Buy |
+1,057
| New | +$436K | 0.52% | 53 |
|
Other funds holding REGN
Virtus ETF Advisers's REGN Position: Q4 2025 in Review
Virtus ETF Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 100 shares — an estimated $56.2K sold.
Virtus ETF Advisers first reported a position in REGN in Q1 2016 and held it in 37 quarters. The position peaked at $1.34M in Q2 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.
- Virtus ETF Advisers reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Virtus ETF Advisers sold 100 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $56.2K.
- Virtus ETF Advisers first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 37 quarters.
- Virtus ETF Advisers's Regeneron Pharmaceuticals position peaked at $1.34M in Q2 2024.
- 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.
Based on Virtus ETF Advisers's 13F filing for Q4 2025, filed 13 Feb 2026.